Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Aziyo Biologics ( (ELUT) ) has issued an update.
On May 29, 2025, Elutia Inc. conducted its annual meeting of stockholders, with 80.9% of Class A common stock represented. During the meeting, two Class II directors were elected to serve until 2028, and the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2025 was ratified.
The most recent analyst rating on (ELUT) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Aziyo Biologics stock, see the ELUT Stock Forecast page.
Spark’s Take on ELUT Stock
According to Spark, TipRanks’ AI Analyst, ELUT is a Neutral.
Elutia Inc.’s stock score is primarily impacted by its challenging financial performance, characterized by negative cash flows and high leverage. The technical analysis also points to bearish market sentiment. While the earnings call provided positive insights into strategic partnerships and operational improvements, these factors are not enough to offset the financial weaknesses.
To see Spark’s full report on ELUT stock, click here.
More about Aziyo Biologics
Average Trading Volume: 43,573
Technical Sentiment Signal: Sell
Current Market Cap: $72.36M
See more insights into ELUT stock on TipRanks’ Stock Analysis page.